Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) — Market Cap & Net Worth
Market Cap & Net Worth: Jazz Pharmaceuticals PLC (JAZZ)
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has a market capitalization of $14.17 Billion ($14.17 Billion) as of June 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1710 globally and #649 in its home market, demonstrating a -3.96% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jazz Pharmaceuticals PLC's stock price $230.56 by its total outstanding shares 62742820 (62.74 Million). Review JAZZ current and long-term liabilities to assess the company's total debt and financial obligations.
Jazz Pharmaceuticals PLC Market Cap History: 2015 to 2026
Jazz Pharmaceuticals PLC's market capitalization history from 2015 to 2026. Data shows growth from $8.82 Billion to $14.47 Billion (5.05% CAGR).
Index Memberships
Jazz Pharmaceuticals PLC is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.28 Trillion | 0.43% | #14 of 24 |
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.58% | #27 of 976 |
|
NASDAQ Composite
IXIC
|
$40.95 Trillion | 0.03% | #195 of 3165 |
|
S&P Midcap 400
MID
|
$3.56 Trillion | 0.25% | #49 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.83% | #19 of 263 |
Weight: Jazz Pharmaceuticals PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jazz Pharmaceuticals PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jazz Pharmaceuticals PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.50x
Jazz Pharmaceuticals PLC's market cap is 2.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $6.84 Billion | $1.49 Billion | $396.83 Million | 4.60x | 17.24x |
| 2017 | $8.45 Billion | $1.62 Billion | $487.85 Million | 5.22x | 17.32x |
| 2018 | $7.78 Billion | $1.89 Billion | $447.10 Million | 4.11x | 17.40x |
| 2019 | $9.37 Billion | $2.16 Billion | $523.37 Million | 4.33x | 17.90x |
| 2020 | $10.36 Billion | $2.36 Billion | $238.62 Million | 4.38x | 43.40x |
| 2021 | $7.99 Billion | $3.09 Billion | -$328.95 Million | 2.58x | N/A |
| 2022 | $10.00 Billion | $3.66 Billion | -$224.06 Million | 2.73x | N/A |
| 2023 | $7.72 Billion | $3.83 Billion | $414.83 Million | 2.01x | 18.60x |
| 2024 | $7.73 Billion | $4.07 Billion | $560.12 Million | 1.90x | 13.79x |
| 2025 | $10.67 Billion | $4.27 Billion | -$356.15 Million | 2.50x | N/A |
Competitor Companies of JAZZ by Market Capitalization
Companies near Jazz Pharmaceuticals PLC in the global market cap rankings as of June 15, 2026.
Key companies related to Jazz Pharmaceuticals PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
Jazz Pharmaceuticals PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Jazz Pharmaceuticals PLC's market cap moved from $8.82 Billion to $ 14.47 Billion, with a yearly change of 5.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.47 Billion | +35.62% |
| 2025 | $10.67 Billion | +38.04% |
| 2024 | $7.73 Billion | +0.12% |
| 2023 | $7.72 Billion | -22.79% |
| 2022 | $10.00 Billion | +25.05% |
| 2021 | $7.99 Billion | -22.81% |
| 2020 | $10.36 Billion | +10.56% |
| 2019 | $9.37 Billion | +20.43% |
| 2018 | $7.78 Billion | -7.94% |
| 2017 | $8.45 Billion | +23.50% |
| 2016 | $6.84 Billion | -22.43% |
| 2015 | $8.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of Jazz Pharmaceuticals PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.17 Billion USD |
| MoneyControl | $14.17 Billion USD |
| MarketWatch | $14.17 Billion USD |
| marketcap.company | $14.17 Billion USD |
| Reuters | $14.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more